@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://bio2rdf.org/drugbank_resource:DB00726_DB01072_nanopub.RATudmItIK9ZUdhge83FuZ5YJa0P6PXba9kwzF_O9bMmI> .
@prefix sub: <http://bio2rdf.org/drugbank_resource:DB00726_DB01072_nanopub.RATudmItIK9ZUdhge83FuZ5YJa0P6PXba9kwzF_O9bMmI#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix has-source: <http://semanticscience.org/resource/SIO_000253> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:publicationInfo ;
    a np:Nanopublication .
}
sub:assertion {
   d:DB00726 dv:ddi-interactor-in dr:DB00726_DB01072 .
  d:DB01072 dv:ddi-interactor-in dr:DB00726_DB01072 .
  dr:DB00726_DB01072 dcterms:identifier "drugbank_resource:DB00726_DB01072" ;
    dcterms:title "DDI between Trimipramine and Atazanavir - The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Atazanavir is initiated, discontinued or dose changed."@en ;
    a dv:Drug-Drug-Interaction ;
    rdfs:label "DDI between Trimipramine and Atazanavir - The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Atazanavir is initiated, discontinued or dose changed. [drugbank_resource:DB00726_DB01072]"@en .
}
sub:provenance {
   sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}
sub:publicationInfo {
   sub:signature.MC0CFQCLfmOfxgGi npx:hasPublicKey "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" ;
    npx:hasSignature "MC0CFQCLfmOfxgGiU1c/ZSKbIM0OF0RSpgIUUQkSVnTqSOzNvBkEZtZTA7gsbS4=" ;
    npx:signedBy instance: .
  this: dcterms:created "2018-03-30T11:12:45.064+02:00"^^xsd:dateTime ;
    dcterms:license <https://creativecommons.org/licenses/by-nc/4.0/> ;
    npx:hasSignatureElement sub:signature.MC0CFQCLfmOfxgGi ;
    prov:wasGeneratedBy process: .
  instance: prov:specializationOf codebase: ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11" ;
    prov:used version: ;
    prov:wasAssociatedWith instance: ;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  version: dcterms:isVersionOf codebase: ;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349" ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}